Tags

Type your tag names separated by a space and hit enter

Specific antibody response after influenza immunization in systemic lupus erythematosus.
J Rheumatol. 2002 Dec; 29(12):2555-7.JR

Abstract

OBJECTIVE

To determine the efficacy of influenza virus vaccine in patients with systemic lupus erythematosus (SLE).

METHODS

The study population comprised 24 patients with SLE who received the split-virion, inactivated vaccine containing 15 micro g hemagglutinin (HA)/dose of each of A/Beijing/262/95(H1N1), A/Sydney/05/97(H3N2), and B/Harbin/07/94. Hemagglutination inhibition (HI) antibodies were tested using the HI test according to a standard World Health Organization procedure. Immune response was defined as 4-fold or greater rise in HI antibodies 6 weeks after vaccination. Geometric mean titers (GMT) were calculated to assess the immunity of the whole group.

RESULTS

All patients were women. Prior to vaccination, the percentage of SLE patients with protective levels of HI antibodies and the GMT of HI antibodies were similar to those of age matched healthy women. Six weeks after vaccination, 75% of the patients had immune response to at least one of the 3 antigens; 58.3% and 62.5% of the patients responded to A/Sydney/05/97(H3N2) and B/Harbin/07/94, respectively. However, only 37.5% of the patients responded to A/Beijing/262/95(H1N1). Six weeks after immunization, the SLE patients generated immune response against a mean number of 1.5 of the 3 influenza vaccines. There was a trend toward a lower immune response in patients with age > or = 50 years, prednisone dosage > or = 10 mg daily, and who used azathioprine. However, methotrexate therapy was not associated with decreased response.

CONCLUSION

The immune response to influenza vaccine of patients with SLE is lower than that seen in adults in the general population, in particular among older patients and those treated with immunosuppressive therapy.

Authors+Show Affiliations

Abu-Shakra M
Department of Medicine, Soroka Medical Center and Ben-Gurion University, Tel-Hashomer, Israel. mahmoud@bgumail.bgu.ac.il
Press J
No affiliation info available
Varsano N
No affiliation info available
Levy V
No affiliation info available
Mendelson E
No affiliation info available
Sukenik S
No affiliation info available
Buskila D
No affiliation info available

MeSH

AdultAgedAntibodies, ViralFemaleHemagglutination Inhibition TestsHemagglutinins, ViralHumansInfluenza VaccinesLupus Erythematosus, SystemicMiddle AgedSeverity of Illness IndexVaccinationVaccines, Inactivated

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12465151

Clinical Trial Links

Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine
Influenza Vaccination in Immunocompromized Patients

Citation

Abu-Shakra, Mahmoud, et al. "Specific Antibody Response After Influenza Immunization in Systemic Lupus Erythematosus." The Journal of Rheumatology, vol. 29, no. 12, 2002, pp. 2555-7.
Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002;29(12):2555-7.
Abu-Shakra, M., Press, J., Varsano, N., Levy, V., Mendelson, E., Sukenik, S., & Buskila, D. (2002). Specific antibody response after influenza immunization in systemic lupus erythematosus. The Journal of Rheumatology, 29(12), 2555-7.
Abu-Shakra M, et al. Specific Antibody Response After Influenza Immunization in Systemic Lupus Erythematosus. J Rheumatol. 2002;29(12):2555-7. PubMed PMID: 12465151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Specific antibody response after influenza immunization in systemic lupus erythematosus. AU - Abu-Shakra,Mahmoud, AU - Press,Joseph, AU - Varsano,Noemi, AU - Levy,Virginia, AU - Mendelson,Ella, AU - Sukenik,Shaul, AU - Buskila,Dan, PY - 2002/12/5/pubmed PY - 2003/5/8/medline PY - 2002/12/5/entrez SP - 2555 EP - 7 JF - The Journal of rheumatology JO - J Rheumatol VL - 29 IS - 12 N2 - OBJECTIVE: To determine the efficacy of influenza virus vaccine in patients with systemic lupus erythematosus (SLE). METHODS: The study population comprised 24 patients with SLE who received the split-virion, inactivated vaccine containing 15 micro g hemagglutinin (HA)/dose of each of A/Beijing/262/95(H1N1), A/Sydney/05/97(H3N2), and B/Harbin/07/94. Hemagglutination inhibition (HI) antibodies were tested using the HI test according to a standard World Health Organization procedure. Immune response was defined as 4-fold or greater rise in HI antibodies 6 weeks after vaccination. Geometric mean titers (GMT) were calculated to assess the immunity of the whole group. RESULTS: All patients were women. Prior to vaccination, the percentage of SLE patients with protective levels of HI antibodies and the GMT of HI antibodies were similar to those of age matched healthy women. Six weeks after vaccination, 75% of the patients had immune response to at least one of the 3 antigens; 58.3% and 62.5% of the patients responded to A/Sydney/05/97(H3N2) and B/Harbin/07/94, respectively. However, only 37.5% of the patients responded to A/Beijing/262/95(H1N1). Six weeks after immunization, the SLE patients generated immune response against a mean number of 1.5 of the 3 influenza vaccines. There was a trend toward a lower immune response in patients with age > or = 50 years, prednisone dosage > or = 10 mg daily, and who used azathioprine. However, methotrexate therapy was not associated with decreased response. CONCLUSION: The immune response to influenza vaccine of patients with SLE is lower than that seen in adults in the general population, in particular among older patients and those treated with immunosuppressive therapy. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/12465151/Specific_antibody_response_after_influenza_immunization_in_systemic_lupus_erythematosus_ DB - PRIME DP - Unbound Medicine ER -